Early post-treatment pseudo-progression amongst glioblastoma multiforme patients treated with radiotherapy and temozolomide: A retrospective analysis

Journal of Medical Imaging and Radiation Oncology

Volumn 55, Issue 6, 2011, Pages 603-610

  Gunjur, Ashray ^a   Lau, Eddie ^a,b   Taouk, Yamna ^b   Ryan, Gail ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

early progression; glioblastoma multiforme; pseudo progression; radiotherapy; temozolomide

Indexed keywords

TEMOZOLOMIDE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURVIVAL; COMPUTER ASSISTED RADIOTHERAPY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; FOLLOW UP; GLIOBLASTOMA; HEALTH CARE QUALITY; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; DACARBAZINE; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 82955169614     PISSN: 17549477     EISSN: 17549485     Source Type: Journal    
DOI: 10.1111/j.1754-9485.2011.02319.x     Document Type: Article

References (24)

1. Rosenthal MA, Drummond KJ, Dally M, et al,. Management of glioma in Victoria (1998-2000): retrospective cohort study. J Clin Neurosci 2006; 184: 270-3.
2. Stupp R, Mason WP, van den Bent MJ, et al,. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96. (Pubitemid 40349501)
3. Macdonald DR, Cascino TL, Schold SC, Cairncross JG,. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 1277-80. (Pubitemid 20195640)
4. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ,. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008; 9: 453-61. (Pubitemid 351597795)
5. Giglio P, Gilbert MR,. Cerebral radiation necrosis. Neurologist 2003; 9: 180-8. (Pubitemid 36944725)
6. Sorensen AG, Batchelor TT, Wen PY, Zhang WT, Jain RK,. Response criteria for glioma. Nat Clin Pract Oncol 2008; 5: 634-44.
7. SPSS Statistics 17.0. SPSS Inc., Chicago, IL, 2008.
8. Cytel Studio 7.0.0. Cytel Software Corporation, Cambridge, MA, 2005.
9. S-Plus 2000. MathSoft Inc., Seattle, WA, 1999.
10. Hoffman WF, Levin VA, Wilson CB,. Evaluation of malignant glioma patients during the postirradiation period. J Neurosurg 1979; 50: 624-8. (Pubitemid 9178240)
11. de Wit MC, de Bruin HG, Eijkenboom W, Sillevis, Smitt PA, van den Bent MJ,. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 2004; 63: 535-7. (Pubitemid 39031388)
12. Chamberlain MC, Glantz MJ, Chalmers L, Van Horn A, Sloan AE,. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 2007; 82: 81-3.
13. Taal W, Brandsma D, Bruin HGD, et al,. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008; 113: 405-10.
14. Brandes AA, Franceschi E, Tosoni A, et al,. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008; 26: 2192-7.
15. Gerstner ER, McNamara MB, Norden AD, LaFrankie D, Wen PY,. Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J Neurooncol 2009; 94: 97-101.
16. Sanghera P, Perry J, Sahgal A, et al,. Pseudoprogression following chemoradiotherapy for glioblastoma multiforme. Can J Neurol Sci 2010; 37: 36-42.
17. Stupp R, Hegi ME, Mason WP, et al,. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-66.
18. Kang HC, Kim CY, Han JH, et al,. Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53. J Neurooncol 2011; 102: 157-62.
19. Vredenburgh JJ, Desjardins A, Herndon JE, et al,. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25: 4722-9. (Pubitemid 350086473)
20. Wen PY, Macdonald DR, Reardon DA, et al,. Updated response assessment criteria for high-grade gliomas: response assessment in Neuro-Oncology Working Group. J Clin Oncol 2010; 28: 1963-72.
21. Clarke JL, Abrey LE, Karimi S, Lassman AB,. Pseudoprogression (PsPr) after concurrent radiotherapy (RT) and temozolomide (TMZ) for newly diagnosed glioblastoma multiforme (GBM). J Clin Oncol 2008; 26: May 20 Suppl; abstr 2025.
22. Dhermain FG, Hau P, Lanfermann H, Jacobs AH, van den Bent MJ,. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol 2010; 9: 906-20.
23. Tsien C, Galban CJ, Chenevert TL, et al,. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol 2010; 28: 2293-9.
24. Piroth MD, Pinkawa M, Holy R, et al,. Prognostic value of early (18F) fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2011; 80: 176-84.